Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Soleno Therapeutics (SLNO) Non-Current Debt (2025)

Soleno Therapeutics (SLNO) has disclosed Non-Current Debt for 1 consecutive years, with $49.9 million as the latest value for Q4 2025.

For Q4 2025, Non-Current Debt changed N/A year-over-year to $49.9 million; the TTM value through Dec 2025 reached $49.9 million, changed N/A, while the annual FY2025 figure was $49.9 million, N/A changed from the prior year.
Non-Current Debt hit $49.9 million in Q4 2025 for Soleno Therapeutics, roughly flat from $49.9 million in the prior quarter.
Across five years, Non-Current Debt topped out at $49.9 million in Q4 2025 and bottomed at $49.8 million in Q1 2025.